32 provisions
Title and introductory text
2025 No. 317
MEDICINES
FEES AND CHARGES
The Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025
Made
at 10.02 a.m. on 11th March 2025
Laid before Parliament
at 4.00 p.m. on 11th March 2025
Laid before the Northern Ireland Assembly
at 4.00 p.m. on 11th March 2025
Coming into force
1st April 2025
The Secretary of State in relation to England and Wales and Scotland, and the Department of Health in Northern Ireland and the Secretary of State acting jointly in relation to Northern Ireland, make these Regulations in exercise of the powers conferred by section 2(1), 6(1)(a) and 43(2) of the Medicines and Medical Devices Act 2021.
The Secretary of State and the Department of Health in Northern Ireland have carried out a public consultation in accordance with section 45(1) of that Act.
In accordance with section 2(2) to (4) of that Act, the Secretary of State’s and the Department of Health in Northern Ireland’s overarching objective in making these Regulations is safeguarding public health, and the Secretary of State and the Department of Health in Northern Ireland have had regard to the matters specified in section 2(3) of that Act and consider that, where these Regulations may have an impact on the safety of human medicines, the benefits of making these Regulations outweigh the risks.
Propose a change1 Citation, commencement and extent
(1) These Regulations may be cited as the Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025.
(2) These Regulations come into force on 1st April 2025.
(3) These Regulations extend to England and Wales, Scotland and Northern Ireland.
Propose a change2 Amendment of the Medicines (Products for Human Use) (Fees) Regulations 2016
The Medicines (Products for Human Use) (Fees) Regulations 2016 are amended in accordance with regulations 3 to 31.
Propose a change3 New regulation 3A
After regulation 3 (interpretation of Part 2), insert—
Fee for scientific or other advice
3A (1) Unless regulation 5 applies, the fee specified in paragraph (2) is payable by a person with whom the licensing authority holds a meeting in order to provide scientific or other advice relating to a medicinal product.
(2) The fee payable by a person in relation to a meeting referred to in paragraph (1) is—
(a) £17,516, if the advice provided at that meeting is on a matter of high complexity;
(b) £13,137, if the advice provided at that meeting is on a matter of medium complexity;
(c) £8,758, if the advice provided at that meeting is on a matter of low complexity;
(d) £986, if the advice provided at that meeting is on a matter of simple complexity.
(3) In paragraph (2), a matter is of—
(a) high complexity if it requires more than twelve assessor days;
(b) medium complexity if it requires more than seven, but not more than twelve, assessor days;
(c) low complexity if it requires more than three, but not more than seven, assessor days;
(d) simple complexity if it requires not more than three assessor days.
(4) If the person paying the fee in accordance with paragraph (1) consents, the licensing authority may provide any advice in writing instead of at a meeting.
(5) In this regulation—
“assessor day” means—
in the case of an assessor who is a member of the senior civil service, one assessor working for one day;
in the case of an assessor who is not a member of the senior civil service, one assessor working for two days.
“medicinal product”, in paragraph (e) of the definition of scientific or other advice in this regulation, includes a substance incorporated in a device which, if used separately, may be considered to be a medicinal product as defined in Article 1(2) of the 2001 Directive;
“scientific or other advice” includes—
scientific advice on an application for an EU marketing authorisation, or an application for the variation of an EU marketing authorisation, in relation to a medicinal product;
advice before the publication of advertising of a medicinal product by the holder of a marketing authorisation for that product on whether that advertising conforms to the requirements of the Human Medicines Regulations;
pharmacovigilance advice;
regulatory advice;
advice in relation to—
scientific or regulatory issues relating to the development of a medicinal product or a type of medicinal product;
the design of pharmaceutical or pre-clinical tests, or clinical trials, for a medicinal product or a type of medicinal product;
the management of risk in relation to a medicinal product or a type of medicinal product which is under development, or is being marketed;
other scientific or regulatory issues relating to a medicinal product or a type of medicinal product after an EU marketing authorisation has been granted for that product or a product of that type.
.
Propose a change4 Omission of regulation 4
Omit regulation 4 (fee for scientific advice: application for, or variation to, EU marketing authorisation).
Propose a change5 Amendment of regulation 5
In regulation 5(1) (fee for scientific advice: classification of a medicinal product)—
(a) in sub-paragraph (a), for “£3,039” substitute “£8,758”;
(b) in sub-paragraph (b), for “£3,986” substitute “£8,758”.
Propose a change6 Omission of regulation 6
Omit regulation 6 (fee for advertising advice).
Propose a change7 Omission of regulation 7
Omit regulation 7 (fee for pharmacovigilance advice).
Propose a change8 Amendment of regulation 8
In regulation 8 (fee for advice on labelling or leaflets), for “£2,421” substitute “£3,757”.
Propose a change9 Omission of regulation 9
Omit regulation 9 (fee for regulatory advice).
Propose a change10 Omission of regulation 10
Omit regulation 10 (fee for advice for other purposes).
Propose a change11 Amendment of regulation 10A
In regulation 10A(1) (waiver for advice given to small and medium companies), for “4 to 10” substitute “3A to 8”.
Propose a change12 Amendment of regulation 11
In regulation 11 (time for payment of fees under regulations 4 to 10), for “4 to 10”, in each place it occurs (including the heading to the regulation), substitute “3A to 8”.
Propose a change13 Amendment of regulation 14
In regulation 14 (fee for applications for additional copy certificates), for “£75” substitute “£82”.
Propose a change14 Amendment of regulation 15
In regulation 15 (fees for applications for certificates and copy certificates by exporters of medicinal products)—
(a) in paragraph (1)(a), for “£167” substitute “£182”;
(b) in paragraph (1)(b), for “£75” substitute “£82”.
Propose a change15 Amendment of regulation 19A
In regulation 19A (fees for certification of plasma master files)—
(a) in paragraph (1), for “£9,140” substitute “£11,126”;
(b) in paragraph (2)(a), for “£344” substitute “£419”;
(c) in paragraph (2)(b), for “£1,308” substitute “£1,593”.
Propose a change16 Amendment of regulation 19B
In regulation 19B (fee for certification of vaccine antigen master files), for “£9,140” substitute “£11,126”.
Propose a change17 Amendment of regulation 19C
In regulation 19C (fees for assessment of post-authorisation safety studies) for “£9,140”, in both places it occurs, substitute “£9,949”.
Propose a change18 Amendment of regulation 19E
In regulation 19E(2) (fee for assessment of periodic safety update reports)—
(a) in sub-paragraph (a), for “£979” substitute “£1,066”;
(b) in sub-paragraph (b), for “£490” substitute “£534”.
Propose a change19 Amendment of regulation 19EA
In regulation 19EA (fee for assessment of clinical trial annual safety reports), for “£248” substitute “£343”.
Propose a change20 Amendment of regulation 21
In regulation 21(1) (fees for notification of changes and reports for broker’s registrations), for “£283” substitute “£345”.
Propose a change21 Amendment of regulation 22
In regulation 22(1) (fees for notification of changes and compliance reports for active substance registrations), for “£283” substitute “£309”.
Propose a change22 Amendment of regulation 27
In regulation 27(1) (fees for renewals of certain manufacturer’s licences), for “£196” substitute “£214”.
Propose a change23 Amendment of regulation 41
In regulation 41 (fees for applications for membership and certificates)—
(a) in paragraph (1), for “£129” substitute “£141”;
(b) in paragraph (2), for “£68” substitute “£75”.
Propose a change24 Amendment of regulation 42
In regulation 42(1) (fee for a review upon oral representations or a person appointed hearing), for “£11,000” substitute “£11,974”.
Propose a change25 Amendment of regulation 44
In regulation 44(1) (interpretation), in the definition of “standard variation”—
(a) in sub-paragraph (o), at the end, omit “or”;
(b) in sub-paragraph (p), for “authorisation.” substitute “authorisation; or”;
(c) after sub-paragraph (p), insert—
(q) a change to any packaging of the product, including the container or other form of packaging immediately in contact with the medicinal product, any packaging into which the container or other form of packaging immediately in contact with the product is placed, or to a leaflet that accompanies the product and contains information for the user of the product.
.
Propose a change26 Amendment of regulation 47
In regulation 47 (fees for variations of certificates)—
(a) in paragraph (1)(a)—
(i) in paragraph (i), for “£123” substitute “£149”;
(ii) in paragraph (ii), for “£62” substitute “£75”;
(b) in paragraph (1)(b), for “£123” substitute “£149”;
(c) in paragraph (2)(a)—
(i) in paragraph (i), for “£243” substitute “£296”;
(ii) in paragraph (ii), for “£243” substitute “£296”;
(iii) in paragraph (iii), for “£123” substitute “£149”;
(iv) in paragraph (iv), for “£62” substitute “£75”;
(d) in paragraph (2)(b), for “£243” substitute “£296”.
Propose a change27 Amendment of Schedule 2
(1) Schedule 2 (capital fees for applications for, and variations to, marketing authorisations, licences, registrations and certificates) is amended as follows.
(2) In paragraph 21 (standard variation application for a homoeopathic medicinal product)—
(a) in sub-paragraph (o), at the end, omit “or”;
(b) in sub-paragraph (p), for “Directive.” substitute “Directive; or”;
(c) after sub-paragraph (p), insert—
(q) a change to any packaging of the product, including the container or other form of packaging immediately in contact with the medicinal product, any packaging into which the container or other form of packaging immediately in contact with the product is placed, or to a leaflet that accompanies the product and contains information for the user of the product.
.
(3) In paragraph 24(5) (marketing authorisations), in the table (fees for marketing authorisation applications)—
(a) in item 1 (major application)—
(i) in entry (a), for “£32,705” substitute “£39,811”;
(ii) in entries (b) to (d), for “£68,663”, in each place it occurs, substitute “£83,580”;
(iii) in entry (e), for “£20,281” substitute “£24,688”;
(iv) omit entry (f);
(v) omit entry (g);
(vi) in entry (h), for “£102,028” substitute “£124,194”;
(b) in item 2 (complex application)—
(i) in entries (a) to (c), for “£19,063”, in each place it occurs, substitute “£23,205”;
(ii) in entry (d), for “£11,487” substitute “£13,983”;
(iii) omit entry (e);
(iv) omit entry (f);
(v) in entry (g), for “£28,207” substitute “£34,335”;
(c) in item 3 (standard application)—
(i) in entries (a) to (c), for “£6,985”, in each place it occurs, substitute “£8,503”;
(ii) in entry (d), for “£6,361” substitute “£7,743”;
(iii) omit entry (e);
(iv) omit entry (f);
(v) in entry (g), for “£10,342” substitute “£12,589”;
(d) in item 4 (simple application)—
(i) in entries (a) to (c), for “£2,820”, in each place it occurs, substitute “£3,433”;
(ii) omit entry (d);
(iii) omit entry (e);
(iv) in entry (f), for “£2,820” substitute “£3,433”;
(e) in item 5 (parallel import licence applications)—
(i) in entry (a), for “£1,971” substitute “£2,400”;
(ii) in entry (b), for “£8,722” substitute “£10,617”;
(iii) in entry (c), for “£19,998” substitute “£24,343”;
(f) in item 6 (change of ownership application), for “£486” substitute “£592”.
(4) In paragraph 25(1) (fees where application includes reclassification)—
(a) in sub-paragraph (a), for “£33,003” substitute “£40,173”;
(b) in sub-paragraph (b), for “£8,978” substitute “£10,929”.
(5) In paragraph 28(4)(b) (application for multiple authorisations), for “£1,308” substitute “£1,593”.
(6) In paragraph 28A (application by pre-assessment of modules)—
(a) in sub-paragraphs (1)(a) to (c), for “£25,507”, in each place it occurs, substitute “£31,049”;
(b) in sub-paragraphs (2)(a) to (c), for “£4,766”, in each place it occurs, substitute “£5,802”.
(7) In paragraph 29 (authorisation for a national homoeopathic product)—
(a) in sub-paragraph (4), in the table (fees for homoeopathic marketing authorisation applications)—
(i) in the second column (fee for applications in respect of products prepared from not more than 5 homoeopathic stocks)—
(aa) in entry 1, for “£517” substitute “£630”;
(bb) in entry 2, for “£808” substitute “£984”;
(cc) in entry 3, for “£1,088” substitute “£1,325”;
(ii) in the third column (fee for other applications)—
(aa) in entry 1, for “£732” substitute “£892”;
(bb) in entry 2, for “£1,014” substitute “£1,235”;
(cc) in entry 3, for “£1,312” substitute “£1,598”;
(b) in sub-paragraph (6), for “£2,154” substitute “£2,622”;
(c) in sub-paragraph (7), for “£7,185” substitute “£8,746”;
(d) in sub-paragraph (8), for “£635” substitute “£773”.
(8) In paragraph 30(1) (manufacturer’s licences and authorisations)—
(a) in sub-paragraph (a), for “£201” substitute “£245”;
(b) in sub-paragraph (b), for “£378” substitute “£461”;
(c) in sub-paragraph (c), for “£3,457” substitute “£4,209”.
(9) In paragraph 31 (wholesale dealer’s licences)—
(a) in sub-paragraph (1), for “£1,983” substitute “£2,159”;
(b) in sub-paragraph (5), for “£439” substitute “£478”.
(10) In paragraph 33(1) (active substance registrations)—
(a) in paragraph (a), for “£3,457” substitute “£3,763”;
(b) in paragraph (b), for “£1,983” substitute “£2,159”.
(11) In paragraph 34 (clinical trial authorisations)—
(a) in sub-paragraph (a), for “£3,366” substitute “£4,656”;
(b) in sub-paragraph (b), for “£248” substitute “£343”.
(12) In paragraph 35 (traditional herbal registrations)—
(a) in sub-paragraph (1), in the second column (fee payable) of the table (fee for application for traditional herbal registration)—
(i) in entry 1 (complex registration application)—
(aa) in entry (a), for “£4,846” substitute “£5,899”;
(bb) in entry (b), for “£7,269” substitute “£8,848”;
(ii) in entry 2 (standard registration application)—
(aa) in entry (a), for “£2,423” substitute “£2,950”;
(bb) in entry (b), for “£3,634” substitute “£4,424”;
(iii) in entry 3 (reduced registration application category II)—
(aa) in entry (a), for “£807” substitute “£983”;
(bb) in entry (b), for “£1,212” substitute “£1,476”;
(iv) in entry 4 (reduced registration application category I)—
(aa) in entry (a), for “£539” substitute “£657”;
(bb) in entry (b), for “£807” substitute “£983”;
(v) in entry 5 (change of ownership application), for “£486” substitute “£592”.
(b) in sub-paragraph (3)—
(i) in paragraph (a), for “£1,077” substitute “£1,311”;
(ii) in paragraph (b), for “£2,154” substitute “£2,622”;
(c) in sub-paragraph (4), for “£7,186” substitute “£8,748”;
(d) in sub-paragraph (5), for “£638” substitute “£777”;
(e) in sub-paragraph (6), for “£2,154” substitute “£2,622”.
(13) In paragraph 35A (early access to medicines scheme fees), in the second column (fee payable) of the table (fees for early access to medicines scheme applications)—
(a) in entry 1, for “£3,986” substitute “£4,852”;
(b) in entry 2, for “£25,643” substitute “£31,214”;
(c) in entry 3, for “£12,821” substitute “£15,607”;
(d) in entry 4, for “£8,309” substitute “£10,115”;
(e) in entry 5, for “£4,154” substitute “£5,057”.
(14) In paragraph 38(6) (marketing authorisations)—
(a) in the second column (column 2 fee payable) of Table 1 (fees for applications for variations of marketing authorisations falling within the scope of Chapter II of Commission Regulation (EC) No 1234/2008)—
(i) in item 1 (application for a single kind variation)—
(aa) in entries (a) and (b), for “£344”, in both places it occurs, substitute “£419”;
(bb) in entry (c), for “£2,742” substitute “£3,338”;
(cc) in entry (d), for “£8,462” substitute “£10,301”;
(ii) in item 2 (applications for a group)—
(aa) in entry (a), for “£344” substitute “£419”;
(bb) in entry (b), for “£1,255” substitute “£1,528”;
(cc) in entry (c), for “£2,973” substitute “£3,619”;
(dd) in entry (d), for “£8,671” substitute “£10,555”;
(b) in the second column (fee payable) of Table 2 (fees for applications for variations of marketing authorisations falling within the scope of Chapter IIa of Commission Regulation (EC) No 1234/2008 and of marketing authorisations in force in Great Britain)—
(i) in item 1, for “£344” substitute “£419”;
(ii) in item 2, for “£1,308” substitute “£1,593”;
(iii) in item 3, for “£9,140” substitute “£11,126”;
(iv) in item 4, for “£33,003” substitute “£40,173”;
(v) in item 5, for “£684” substitute “£833”;
(vi) in item 6, for “£1,817” substitute “£2,212”;
(vii) in item 7, for “£9,911” substitute “£12,065”;
(viii) in item 8, for “£28,904” substitute “£35,184”;
(c) in the second column (fee payable) of Table 3 (fees for reclassification variation applications)—
(i) in entry (a), for “£33,003” substitute “£40,173”;
(ii) in entry (b), for “£8,978” substitute “£10,929”.
(15) In paragraph 40(1) (reclassification of marketing authorisations), for “£1,308” substitute “£1,593”.
(16) In paragraph 41 (variation of marketing authorisation: national homoeopathic products)—
(a) in sub-paragraph (a), for “£243” substitute “£296”;
(b) in sub-paragraph (b), for “£374” substitute “£456”;
(c) in sub-paragraph (c), for “£123” substitute “£149”.
(17) In paragraph 42(1) (variation of parallel import licence)—
(a) in paragraph (a), for “£33,003” substitute “£40,173”;
(b) in paragraph (b), for “£8,978” substitute “£10,929”;
(c) in paragraph (c), for “£393” substitute “£479”.
(18) In paragraph 43 (manufacturer’s authorisations and licences)—
(a) in sub-paragraph (a), for “£283” substitute “£345”;
(b) in sub-paragraph (b), for “£565” substitute “£688”.
(19) In paragraph 44 (variation of manufacturer’s authorisations and licences), for “£283” substitute “£345”.
(20) In paragraph 45 (wholesale dealer’s licences), for “£535” substitute “£652”.
(21) In paragraph 46 (variation of wholesale dealer’s licence), for “£283” substitute “£345”.
(22) In paragraph 47 (variation of a broker’s registration), for “£283” substitute “£345”.
(23) In paragraph 48 (variation of an active substance registration), for “£283” substitute “£309”.
(24) In paragraph 49(1) (clinical trial authorisations), for “£248” substitute “£302”.
(25) In paragraph 50 (traditional herbal registrations)—
(a) in sub-paragraph (a), for “£240” substitute “£293”;
(b) in sub-paragraph (b), for “£635” substitute “£773”;
(c) in sub-paragraph (c), for “£7,186” substitute “£8,748”;
(d) in sub-paragraph (d), for “£152” substitute “£186”.
(26) In paragraph 54 (a set of changes)—
(a) in sub-paragraph (1)—
(i) in paragraph (a), for “£570” substitute “£992”;
(ii) in paragraph (b), for “£361” substitute “£440”;
(b) in sub-paragraph (2), for “£205” substitute “£224”.
(27) In paragraph 56 (renewal of a marketing authorisation)—
(a) in sub-paragraphs (a) and (b), for “£822”, in both places it occurs, substitute “£1,239”;
(b) in sub-paragraph (c), for “£10,650” substitute “£16,042”.
(28) In paragraph 57(2) (renewal of multiple marketing authorisations)—
(a) in paragraphs (a)(i) and (a)(ii), for “£822”, in both places it occurs, substitute “£1,239”;
(b) in paragraph (b)(i), for “£10,650” substitute “£16,042”.
(29) In paragraph 57A (capital fee for conducting a major safety review)—
(a) in sub-paragraph (a), for “£56,415” substitute “£61,408”;
(b) in sub-paragraph (b), for “£65,555” substitute “£71,357”;
(c) in sub-paragraph (c), for “£74,694” substitute “£81,305”;
(d) in sub-paragraph (d), for “£83,834” substitute “£91,254”.
(30) For paragraph 57B (capital fee for testing of samples by the appropriate authority) substitute—
57B (1) The fee payable under regulation 19F(1) in connection with the submission of a sample of a batch of a medicinal product is £5,093 for each day taken to examine the sample for testing, the appropriate documentation (as defined in regulation 60A of the Human Medicines Regulations) or both (as the case may be), and the fee payable is to be adjusted pro rata for each period taken of less than 1 day.
(2) In this paragraph, a “day” means a period of 8 hours and 30 minutes.
.
Propose a change28 Amendment of Schedule 3
(1) Schedule 3 (fees for inspections) is amended as follows.
(2) In paragraph 2(1) (fees: general)—
(a) in paragraph (1)(a), for “£3,651” substitute “£5,251”;
(b) in paragraph (1)(b), for “£1,825” substitute “£2,625”.
(3) In paragraph 5 (wholesale dealer’s licence: general)—
(a) in sub-paragraphs (a) and (b), for “£2,662”, in both places it occurs, substitute “£4,136”;
(b) in sub-paragraph (b), for “£1,331” substitute “£2,068”.
(4) In paragraph 6(2) (wholesale dealer’s licence: traditional herbal medicinal products)—
(a) in paragraph (a), for “£1,023” substitute “£1,114”;
(b) in paragraphs (b) and (c), for “£1,880”, in both places it occurs, substitute “£2,047”.
(5) In paragraph 7(3) (wholesale dealer’s licences: inspection of short duration), for “£1,331” substitute “£2,068”.
(6) In paragraph 8 (broker’s registrations)—
(a) in sub-paragraph (1)—
(i) in paragraphs (a) and (b), for “£2,662”, in both places it occurs, substitute “£3,241”;
(ii) in paragraph (b), for “£1,331” substitute “£1,621”;
(b) in sub-paragraph (3), for “£640” substitute “£780”.
(7) In paragraph 9 (active substance registrations)—
(a) in sub-paragraph (1)(a)—
(i) in sub-paragraphs (i) and (ii), for “£3,651”, in both places it occurs, substitute “£3,975”;
(ii) in sub-paragraph (ii), for “£1,825” substitute “£1,988”;
(b) in sub-paragraph (1)(b)—
(i) in sub-paragraphs (i) and (ii), for “£2,662”, in both places it occurs, substitute “£2,898”;
(ii) in sub-paragraph (ii), for “£1,331” substitute “£1,449”;
(c) in sub-paragraph (3)—
(i) in paragraph (a), for “£871” substitute “£949”;
(ii) in paragraph (b), for “£640” substitute “£697”.
(8) In paragraph 10 (office-based inspections)—
(a) in sub-paragraph (a), for “£2,562” substitute “£4,924”;
(b) in sub-paragraph (b), for “£1,862” substitute “£3,810”.
Propose a change29 Amendment of Schedule 4
(1) Schedule 4 (Periodic fees for licences) is amended as follows.
(2) In paragraph 5 (marketing authorisations), in column 2 (fee payable) of the table (periodic fees for holding a marketing authorisation)—
(a) in entry 1, for “£10,681” substitute “£11,627”;
(b) in entry 2, for “£338” substitute “£368”;
(c) in entry 3(a), for “£10,681” substitute “£11,627”;
(d) in entry 3(b)(i), for “£2,671” substitute “£2,908”;
(e) in entry 3(b)(ii), for “£1,332” substitute “£1,450”;
(f) in entries 3(b)(iii), (c) and (d), for “£338”, in each place it occurs, substitute “£368”;
(g) in entries 3(e) to (h), for “£84”, in each place it occurs, substitute “£92”.
(3) In paragraph 6 (marketing authorisation: where Part 2 of the Act applies), for “£338” substitute “£368”.
(4) In paragraph 7 (marketing authorisation: derivatives)—
(a) in sub-paragraph (a), for “£10,681” substitute “£11,627”;
(b) in sub-paragraph (b), for “£7,209” substitute “£7,847”.
(5) In paragraph 11(1) and (2) (manufacturer’s licences or manufacturing authorisations), for “£515”, in both places it occurs, substitute “£561”.
(6) In paragraph 12 (wholesale dealer’s licences)—
(a) in sub-paragraph (1), for “£317” substitute “£346”;
(b) in sub-paragraph (2), for “£189” substitute “£206”.
(7) In paragraph 15(1)(b) (additional amount for manufacturer’s licences and wholesale dealer’s licences which relate to special medicinal products)—
(a) for Table 1 (additional periodic fee in connection with notices for imported special medicinal products) substitute—
Table 1 Additional periodic fee in connection with notices for imported special medicinal products
Column 1 | Column 2
Number of special import notices | Additional amount
1 to 20 | £86
21 to 100 | £427
101 to 500 | £2,131
501 to 1,000 | £4,261
1,001 to 2,000 | £8,521
2,001 to 5,000 | £17,042
5,001 to 10,000 | £34,083
10,001 to 15,000 | £51,125
15,001 to 20,000 | £68,166
20,001 to 25,000 | £85,208
25,001 to 30,000 | £102,249
30,001 to 35,000 | £119,291
35,001 to 40,000 | £136,333
40,001 to 45,000 | £153,375
45,001 to 50,000 | £170,417
Each additional 5,000 above 50,000 | £170,417 plus £17,042 for each additional 5,000 special import notices
;
(b) in the second column (additional amount) of Table 2 (Additional periodic fee in connection with the number of different special medicinal products notified for import)—
(i) in the entry “1 to 5”, for “£100” substitute “£122”;
(ii) in the entry “6 to 10”, for “200” substitute “£244”;
(iii) in the entry “11 to 20”, for “£400” substitute “£487”;
(iv) in the entry “21 to 50”, for “£1,000” substitute “£1,218”;
(v) in the entry “51 to 100, for “£2,000” substitute “£2,435”;
(vi) in the entry “101 to 200”, for “£4,000” substitute “£,4,869”;
(vii) in the entry “For each additional 100 special medicinal products notified for import above 200”, for “£2,000” substitute “£4,869 plus £2,435 for each additional 100 special medicinal products notified for import”.
(8) In paragraph 16 (traditional herbal registrations), for “£84” substitute “£92”.
Propose a change30 Amendment of Schedule 5
(1) Schedule 5 (fees for certificates of registration) is amended as follows.
(2) In the table—
(a) in the second column (fees for applications in respect of products prepared from not more than 5 homoeopathic stocks)—
(i) in item 1, for “£159” substitute “£194”;
(ii) in item 2, for “£478” substitute “£582”;
(iii) in item 3, for “£501” substitute “£610”;
(iv) in item 5, for “£430” substitute “£524”;
(v) in item 7, for “£790” substitute “£962”;
(b) in the third column (fees for other applications)—
(i) in item 1, for “£393” substitute “£479”;
(ii) in item 2, for “£704” substitute “£857”;
(iii) in item 3, for “£638” substitute “£777”;
(iv) in item 5, for “£563” substitute “£686”;
(v) in item 7 for “£1,034” substitute “£1,259”.
Propose a change31 Amendment of Schedule 7
(1) Schedule 7 (waiver, reduction or refund of capital fees) is amended as follows.
(2) In paragraph 11(1) (scientific advice: paediatric indications), for “regulation 4” substitute “regulation 3A”.
Propose a change